VERICIGUAT: MODERN THERAPY FOR THE TREATMENT OF CHRONIC HEART FAILURE
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5325Keywords:
Vericiguat, Soluble Guanylate Cyclase (sGC) Stymulator, Heart Failure, Pharmacological Treatment, Cardiovascular OutcomesAbstract
Vericiguat is the first oral soluble guanylate cyclase (sGC) stimulator developed to reduce the risk of cardiovascular death and heart failure–related hospitalizations in patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF). sGC dysfunction, resulting in impaired synthesis of cyclic guanosine monophosphate (cGMP), may play a keyrole in the pathophysiology of heart failure by affecting myocardial function, vascular tone, and peripheral tissue perfusion.
Vericiguat exerts its therapeutic effect by enhancing intracellular cGMP levels, leading to improved cardiac function and vasodilation. Consequently, the drug represents a promising treatment option for patients with HFrEF, particularly those with recent decompensation, requiring intravenous diuretic therapy, or at high risk for rehospitalization due to disease exacerbation.
Clinical efficacy of vericiguat was demonstrated in the VICTORIA trial, which enrolled 6,857 patients with HFrEF following recent decompensation. After a median follow-up of 10.8 months, treatment with vericiguat significantly reduced the risk of the composite endpoint of cardiovascular death or heart failure related hospitalization compared with placebo. Patients with more advanced disease also exhibited reductions in NT-proBNP levels, suggesting a potential biomarker of therapeutic response. Vericiguat is generally well tolerated. The most commonly reported adverse events are hypotension and syncope. The drug can be safely administered to patients with mild to moderate renal or hepatic impairment, although data in severe organ dysfunction are lacking. Dose adjustments are not required based on age or body weight. The introduction of vericiguat into the management of HFrEF represents a meaningful advancement in therapy. While the drug does not significantly extend overall survival, its use is associated with a substantial reduction in the risk of recurrent hospitalizations, which may have important clinical and prognostic implications in this patient population.
References
Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., et al. (2020). Vericiguat in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 382(20), 1883–1893. https://doi.org/10.1056/NEJMoa1915928
Gheorghiade, M., Greene, S. J., Butler, J., Filippatos, G., Lam, C. S. P., Maggioni, A. P., et al. (2015). Effect of vericiguat on NT-proBNP and clinical outcomes in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED randomized trial. JAMA, 314(21), 2251–2262. https://doi.org/10.1001/jama.2015.15734
Pieske, B., Maggioni, A. P., Lam, C. S. P., Pieske-Kraigher, E., Butler, J., Filippatos, G., et al. (2017). Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: Results of the SOCRATES-PRESERVED study. European Heart Journal, 38(15), 1119–1127. https://doi.org/10.1093/eurheartj/ehw593
Armstrong, P. W., Lam, C. S. P., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., O’Connor, C. M., et al. (2020). Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: The VITALITY-HFpEF randomized clinical trial. JAMA, 324(15), 1512–1521. https://doi.org/10.1001/jama.2020.15922
Voors, A. A., Mulder, H., Reyes, E., et al. (2021). Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: Insights from the VICTORIA trial. European Journal of Heart Failure, 23(8), 1313–1321. https://doi.org/10.1002/ejhf.2221
Butler, J., Fioretti, F., McMullan, C. J., Anstrom, K. J., Barash, I., Bonaca, M. P., et al. (2026). Vericiguat and mortality in heart failure and reduced ejection fraction: The VICTOR trial. European Heart Journal, 47(6), 683–697. https://doi.org/10.1093/eurheartj/ehaf655
Tian, J., Dong, M., Sun, X., Jia, X., Zhang, G., Zhang, Y., Lin, Z., Xiao, J., Zhang, X., & Lu, H. (2024). Vericiguat in heart failure with reduced ejection fraction patients on guideline-directed medical therapy: Insights from a 6-month real-world study. International Journal of Cardiology, 417, 132524. https://doi.org/10.1016/j.ijcard.2024.132524
Falco, L., Brescia, B., Catapano, D., Martucci, M. L., Valente, F., Gravino, R., Contaldi, C., Pacileo, G., & Masarone, D. (2023). Vericiguat: The fifth harmony of heart failure with reduced ejection fraction. Journal of Cardiovascular Development and Disease, 10(9), 388. https://doi.org/10.3390/jcdd10090388
González-Juanatey, J. R., Anguita-Sánchez, M., Bayes-Genís, A., Comín-Colet, J., García-Quintana, A., Recio-Mayoral, A., et al. (2022). Vericiguat in heart failure: From scientific evidence to clinical practice. Revista Clínica Española (English Edition), 222(6), 359–369. https://doi.org/10.1016/j.rceng.2021.12.006
Dies, R. M., Jackson, C. N., Flanagan, C. J., Sinnathamby, E. S., Spillers, N. J., Potharaju, P., Singh, N., Varrassi, G., Ahmadzadeh, S., Shekoohi, S., & Kaye, A. D. (2023). The evolving role of vericiguat in patients with chronic heart failure. Cureus, 15(12), e49782. https://doi.org/10.7759/cureus.49782
Lam, C. S. P., Mulder, H., Lopatin, Y., Vazquez-Tanus, J. B., Siu, D., Ezekowitz, J., Pieske, B., O’Connor, C. M., Roessig, L., Patel, M. J., Anstrom, K. J., Hernandez, A. F., Armstrong, P. W., & VICTORIA Study Group. (2021). Blood pressure and safety events with vericiguat in the VICTORIA trial. Journal of the American Heart Association, 10(22), e021094. https://doi.org/10.1161/JAHA.121.021094
Sahana, U., Wehland, M., Simonsen, U., Schulz, H., & Grimm, D. (2023). A systematic review of the effect of vericiguat on patients with heart failure. International Journal of Molecular Sciences, 24(14), 11826. https://doi.org/10.3390/ijms241411826
Fritsch, A., Meyer, M., Blaustein, R. O., Trujillo, M. E., Kauh, E., Roessig, L., Boettcher, M., & Becker, C. (2024). Clinical pharmacokinetic and pharmacodynamic profile of vericiguat. Clinical Pharmacokinetics, 63, 751–771. https://doi.org/10.1007/s40262-024-01384-1
Vannuccini, F., Campora, A., Barilli, M., & Palazzuoli, A. (2022). Vericiguat in heart failure: Characteristics, scientific evidence and potential clinical applications. Biomedicines, 10(10), 2471. https://doi.org/10.3390/biomedicines10102471
Vyas, A., & Onteddu, N. (2025). Vericiguat. In StatPearls. StatPearls Publishing.
Russo, P., Vitiello, L., Milani, F., Volterrani, M., Rosano, G. M. C., Tomino, C., & Bonassi, S. (2024). New therapeutics for heart failure worsening: Focus on vericiguat. Journal of Clinical Medicine, 13(14), 4209. https://doi.org/10.3390/jcm13144209
Chiles, R., & Al-Horani, R. A. (2022). Vericiguat: A new hope for heart failure patients. Cardiovascular Therapeutics, 2022, 1554875. https://doi.org/10.1155/2022/1554875
Trujillo, M. E., Ayalasomayajula, S., Blaustein, R. O., & Gheyas, F. (2023). Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science. Clinical and Translational Science, 16(12), 2458–2466. https://doi.org/10.1111/cts.13677
Rao, V. N., Diez, J., Gustafsson, F., Mentz, R. J., Senni, M., Jankowska, E. A., & Bauersachs, J. (2023). Practical patient care considerations with use of vericiguat after worsening heart failure events. Journal of Cardiac Failure, 29(3), 389–402. https://doi.org/10.1016/j.cardfail.2022.10.431
Vohra, M., Amir, M., Osoro, I., Sharma, A., & Kumar, R. (2023). Impact of vericiguat on heart failure with reduced ejection fraction: A review. Global Health Journal, 7(3), 123–129. https://doi.org/10.1016/j.glohj.2023.07.004
European Society of Cardiology. (2022, May 4). Zalecenia ESC 2021 dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca. https://www.escardio.org
Stasch, J. P., Schlossmann, J., & Hocher, B. (2015). Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence. British Journal of Pharmacology, 172(2), 300–311. https://doi.org/10.1111/bph.12974
Markham, A., & Duggan, S. (2021). Vericiguat: First approval. Drugs, 81, 721–726. https://doi.org/10.1007/s11096-021-03240-1
Aimo, A., Castiglione, V., Vergaro, G., Panichella, G., Senni, M., Lombardi, C. M., & Emdin, M. (2021). The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Failure Reviews, 26(4), 567–577. https://doi.org/10.1007/s10741-021-10122-9
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dominik Bylica, Anna Kaźmierska, Radosław Szydłowski, Magdalena Bodera, Sonja Rozmus
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
